195 related articles for article (PubMed ID: 29472358)
1. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias.
Gerber B; Manzoni M; Spina V; Bruscaggin A; Lionetti M; Fabris S; Barbieri M; Ciceri G; Pompa A; Forestieri G; Lerch E; Servida P; Bertoni F; Zucca E; Ghielmini M; Cortelezzi A; Cavalli F; Stussi G; Baldini L; Rossi D; Neri A
Haematologica; 2018 Jun; 103(6):e245-e248. PubMed ID: 29472358
[No Abstract] [Full Text] [Related]
2. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.
Mazzotti C; Buisson L; Maheo S; Perrot A; Chretien ML; Leleu X; Hulin C; Manier S; Hébraud B; Roussel M; Do Souto L; Attal M; Avet-Loiseau H; Corre J
Blood Adv; 2018 Nov; 2(21):2811-2813. PubMed ID: 30355580
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics Analysis for Cell-Free Tumor DNA Sequencing Data.
Chen S; Liu M; Zhou Y
Methods Mol Biol; 2018; 1754():67-95. PubMed ID: 29536438
[TBL] [Abstract][Full Text] [Related]
4. Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E; Fotiou D; Kastritis E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e905-e909. PubMed ID: 32723621
[TBL] [Abstract][Full Text] [Related]
5. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
6. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
[TBL] [Abstract][Full Text] [Related]
7. Monitoring Melanoma Using Circulating Free DNA.
Diefenbach RJ; Lee JH; Rizos H
Am J Clin Dermatol; 2019 Feb; 20(1):1-12. PubMed ID: 30374893
[TBL] [Abstract][Full Text] [Related]
8. Early detection and monitoring of cancer in liquid biopsy: advances and challenges.
Xue VW; Wong CSC; Cho WCS
Expert Rev Mol Diagn; 2019 Apr; 19(4):273-276. PubMed ID: 30760042
[No Abstract] [Full Text] [Related]
9. Liquid Biopsy for Investigation of Cancer DNA in Esophageal Adenocarcinoma: Cell-Free Plasma DNA and Exosome-Associated DNA.
Smith RA; Lam AK
Methods Mol Biol; 2018; 1756():187-194. PubMed ID: 29600371
[TBL] [Abstract][Full Text] [Related]
10. Liquid Biopsy Technique May Allow Early Screening.
Cancer Discov; 2017 Nov; 7(11):1207. PubMed ID: 28903989
[TBL] [Abstract][Full Text] [Related]
11. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
12. Human herpesvirus 8 genome is not found in whole bone marrow core biopsy specimens of patients with plasma cell dyscrasias.
Drabick JJ; Davis BJ; Lichy JH; Flynn J; Byrd JC
Ann Hematol; 2002 Jun; 81(6):304-7. PubMed ID: 12107558
[TBL] [Abstract][Full Text] [Related]
13. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
14. The Introduction and Clinical Application of Cell-Free Tumor DNA.
Li J; Liu R; Huang C; Chen S; Xu M
Methods Mol Biol; 2018; 1754():45-65. PubMed ID: 29536437
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Circulating Tumor DNA.
Mithraprabhu S; Spencer A
Methods Mol Biol; 2018; 1792():129-145. PubMed ID: 29797256
[TBL] [Abstract][Full Text] [Related]
16. Towards a more sensitive detection of somatic mutations in cell-free DNA.
Earl J
EBioMedicine; 2019 Mar; 41():23. PubMed ID: 30894282
[No Abstract] [Full Text] [Related]
17. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA as a Liquid Biopsy: Current Clinical Applications and Future Directions.
Komatsubara KM; Sacher AG
Oncology (Williston Park); 2017 Aug; 31(8):618-27. PubMed ID: 28812303
[TBL] [Abstract][Full Text] [Related]
19. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
20. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
